#### 

			Remove			
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	4263679		1981-09-28	Erlendson	
	2	4603141		1986-07-29	Giles	
	3	4692147		1987-09-08	Duggan	
	4	4987897		1991-01-29	Funke	
	5	5269301		1993-12-14	Cohen	
	6	5330505		1994-07-19	Cohen	
	7	5331966		1994-07-26	Bennett	
	8	5368040		1994-11-29	Carney	

Application Number		10773965		
Filing Date		2004-02-06		
First Named Inventor Hildeb		orand		
Art Unit		3767		
Examiner Name C. Wit		tczak		
Attorney Docket Number		P0011472.00		

	, ,	T		
9	5417717	1995-05-23	Salo et al.	
10	5564434	1996-10-15	Halperin	
11	5643207	1997-07-01	Rise	
12	5674249	1997-10-07	DeCoriolis et al.	
13	5755737	1998-05-26	Prieve et al.	
14	5782798	1998-07-21	Rise	
15	5807243	1998-09-15	Vierra et al.	
16	5801188	1998-09-01	Hassenbusch III, et al.	
17	5810735	1998-09-22	Halperin	
18	5893881	1999-04-13	Elsberry	
19	5919210	1999-07-06	Lurie et al.	

Application Number		10773965		
Filing Date		2004-02-06		
First Named Inventor Hildet		prand		
Art Unit		3767		
Examiner Name C. Wit		tczak		
Attorney Docket Number		P0011472.00		

	20	6104949		2000-08-15	Pitts Crick et al.			
	21	6280409		2001-08-28	Stone et al.			
	22	6438408		2002-08-20	Mulligan et al.			
If you wis	h to ac	ld additional U.S. Paten			ease click the Add button.		Add	
			U.S.P	ATENT APPLIC	CATION PUBLICATIONS	T	Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Releva	Columns, nt Passag Appear	Lines where les or Relevant
	1	20020049155	A1	2002-10-17	Schmauder			
	2	20020107553	A1	2002-08-08	Hill et al.			
	3	20020120205	A1	2002-08-29	Ferek-Petric			
	4	20020143369	A1	2002-10-03	Hill et al.			
	5	20020165586	A1	2002-11-07	Hill et al.			
	6	20030004549	A	2003-01-02	Hill et al.			

Application Number		10773965		
Filing Date		2004-02-06		
First Named Inventor Hildeb		prand		
Art Unit		3767		
Examiner Name	C. Wi	tczak		
Attorney Docket Number		P0011472.00		

	7	20030045805	A1	2003-03	3-06	Sheldon et al.					
	8	20030083702	A1	2003-05	5-01	Stadler					
	9	20030100925	A1	2003-05	5-29	Pape et al.					
	10	20030204181	A1	2003-10	)-30	Starkebaum					
	11	20040162497	A1	2004-09	)-19	Bennett					
	12	20040167410	A1	2004-08	3-26	Hettrick					
If you wisl	n to a	dd additional U.S. Publi	shed Ap	plication	citation	ո information բ	olease click the Add	butto	n. Add		
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No					Publication Date	Name of Patentee Applicant of cited Document	e or	where Rele	or Relevant	<b>T</b> 5
	1										
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									1		
			NON	I-PATEI	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*  Cite No  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								T5			

Application Number		10773965		
Filing Date		2004-02-06		
First Named Inventor Hildet		prand		
Art Unit		3767		
Examiner Name	C. Wi	tczak		
Attorney Docket Number		P0011472.00		

1		NT et al., "ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: cutive Summary", J. Am. Coll. Cardiol., 38(7): 2101-2113, 2001.							
2	GILE 1980	ES, et al., "Acute Effects of Intravenous Clonidine HCI in Congestive Heart Failure", Circulation II, 62(4) October 0.							
3	EISE	ISENACH, Anethesiology, 74: 766-771, 1991.							
4	AZE	AZEUEDO et al., J. Am. Coll. Cardiol., 33(1): 186-91, 1999.							
5	ESL	ESLER et al., J. Auton. Nervous Sys., 72(2-3): 210-9, 1998.							
6	MAN	MANOLIS et al., Clin. Exp. Hypertens, 20(7): 717-31, 1998.							
7	7 ZHANG et al., J. Cardiol., 65(3): 233-8, 1998.								
8	8 GIRGIS et al., Am. J. Cardiol., 82(3): 335-7, 1998.								
9	9 ZHANG et al., Int. J. Cardiol., 59(2):139-44, 1997.								
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner Sign		Date Considered							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

Application Number		10773965		
Filing Date		2004-02-06		
First Named Inventor Hildet		orand		
Art Unit		3767		
Examiner Name C. Wit		tczak		
Attorney Docket Number		P0011472.00		

<sup>&</sup>lt;sup>1</sup> See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

( Not for submission under 37 CFR 1.99)

Application Number		10773965		
Filing Date		2004-02-06		
First Named Inventor	Hildebrand			
Art Unit		3767		
Examiner Name	C. Witczak			
Attorney Docket Number		P0011472.00		

	CERTIFICATION STATEMENT							
Plea	Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):							
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).							
OR	1							
	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).							
	See attached ce	rtification statement.						
	Fee set forth in 3	37 CFR 1.17 (p) has been submitted herewith	1.					
X	None							
	SIGNATURE  A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.							
Sigr	Signature /Paul H. McDowall/		Date (YYYY-MM-DD)	2006-11-01				
Nan	ne/Print	Paul H. McDowall	Registration Number	34,873				
		rmation is required by 37 CFR 1.97 and 1.98 (and by the USPTO to process) an applicatio	•	•				

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria**,

VA 22313-1450.

#### **Privacy Act Statement**

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a
  court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement
  negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
  - 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.